Actuate Therapeutics Inc
ACTUHealthcare|Biotechnology|US
$0.33
+0.00 (+0.55%)
DCF Value
$0.54
Tangible Book / Share
$0.04
Cash / Share
$0.19
Clinical Trials (11)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT05010629 9-ING-41 Plus Carboplatin in Salivary Gland Carcinoma | Salivary Gland Cancer, Recurrent Salivary Gland Cancer | P2 | Active | 32 | Open-label | 9-ING-41, Carboplatin, Pembrolizumab |
| NCT05077800 FOLFIRINOX + Elraglusib + Losartan In Pancreatic Cancer | Pancreatic Adenocarcinoma, Pancreatic Adenocarcinoma Metastatic | P2 | Active | 70 | RCT, Open-label | FOLFIRNINOX, Losartan, 9-ING-41 |
| NCT03678883 9-ING-41 in Patients With Advanced Cancers | Cancer, Pancreatic Cancer | P2 | Active | 350 | RCT, Open-label | 9-ING-41, Gemcitabine - 21 day cycle, Doxorubicin., Lomustine, Carboplatin., Nab paclitaxel., Paclitaxel., Gemcitabine - 28 day cycle, Irinotecan |
| NCT06896188 9-ING-41 Combined With Retifanlimab, Plus Modified FOLFIRINOX for Patients With Advanced Pancreatic Adenocarcinoma (RiLEY) | Pancreatic Adenocarcinoma | P1 | Recruiting | 12 | Open-label | Retifanlimab, Chemotherapy, 9-ING-41 |
| NCT05239182 9-ING-41 Plus Retifanlimab and Gemcitabine/Nab-Paclitaxel in Patients With Advanced Pancreatic Adenocarcinoma | Pancreatic Adenocarcinoma | P2 | Terminated | 7 | Open-label | 9-ING-41, Retifanlimab, Gemcitabine, Abraxane |
| NCT05116800 Phase 2 Study of 9-ING-41 With Chemotherapy in Sarcoma | Soft Tissue Sarcoma, Undifferentiated Pleomorphic Sarcoma | P2 | Withdrawn | — | Open-label | Gemcitabine, 9-ING-41, Docetaxel |
| NCT04218071 Actuate 1901: 9-ING-41 in Myelofibrosis | Myelofibrosis | P2 | Completed | 17 | Open-label | Ruxolitinib, 9-ING-41 |
| NCT04832438 9-ING-41 Plus Carboplatin in Patients With Advanced, Metastatic Salivary Gland Carcinoma | Salivary Gland Carcinoma, Adenoid Cystic Carcinoma | P2 | Withdrawn | — | Open-label | 9-ING-41, Carboplatin |
| NCT04906876 A Phase 2 Study of 9-ING-41Combined With Chemotherapy in Adolescents and Adults With Advanced Sarcomas | Sarcoma, Soft Tissue Sarcoma | P2 | Withdrawn | — | Open-label | Gemcitabine, Docetaxel, 9-ING-41 |
| NCT07714395 Evaluate Preliminary Anti-tumor Activity of Elraglusib in Adult Participants With Advanced Solid Tumors | Advanced Malignant Solid Tumor | P1P2 | Not Yet Recruiting | 100 | Open-label | Elraglusib Oral Tablets |
| NCT04239092 9-ING-41 in Pediatric Patients With Refractory Malignancies. | Refractory Cancer, Refractory Neoplasm | P1 | Terminated | 40 | Open-label | 9-ING-41, Irinotecan, Temozolomide, Cyclophosphamide, Topotecan |